Pre-loader

Clinical Trials

The articles below are listed in chronological order, newest to oldest.

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)

New drug combo could improve immunotherapy for SCCOHT ovarian cancer

Study: The immune effects of seclidemstat in aggressive ovarian cancer striking young women

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were wrong.

Prolonged survival of small cell ovarian cancer-hypercalcemic type (SCCOHT): Should radiotherapy play a larger role? (Filho et al., 2015)

Is cancer immunotherapy really a miracle cure?

Killing Cancer Through the Immune System

Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary. (Wallbillich et al., 2012)

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. (Pautier et al., 2007)